Summary
Highlights
Dr. Eric Westman introduces a video by Dr. Kevin Ham, who claims that certain foods reduced his arterial plaque by 20-25% in three months. Dr. Westman will analyze Dr. Ham's claims about whether drugs like statins or specific foods are more effective at reducing plaque.
Dr. Westman expresses skepticism about Dr. Ham's personal anecdote, labeling it a 'credible anecdote' but stressing the need for independent verification. He suggests maintaining skepticism even when assuming the claims are true, as personal experiences do not equate to scientific proof.
Dr. Ham states that high-dose statins, while reducing LDL cholesterol by up to 60%, only reduce plaque by 0.015-0.04 mm, which is a very small amount. He argues that statins primarily stop plaque progression rather than actively reversing it, prompting Dr. Westman to distinguish between statistical and clinical significance.
Dr. Ham introduces pomegranate juice as a food that has shown evidence in plaque reduction. He cites a study where 50 ml of pomegranate juice daily for a year reduced arterial wall thickness by 17-30%. This reduction is attributed to a 90% decrease in LDL oxidation and a supercharging of HDL's ability to remove cholesterol from plaque. Dr. Westman questions whether this is absolute or relative risk reduction and notes that pomegranate acts through a different mechanism than statins.
Dr. Ham discusses Nattokinase, a supplement derived from fermented beans, which he claims reduced plaque size and wall thickness by up to 36% in a large retrospective study in China. Nattokinase works by breaking down fibrin, the network upon which plaque builds. Dr. Westman criticizes the retrospective nature of the study, emphasizing that observation does not imply causation.
Dr. Ham combined Nattokinase (with Vitamin K2) and pomegranate juice, resulting in a 20-25% plaque reduction in three months. Dr. Westman remains wary, highlighting the volatility of measurements like blood pressure and cholesterol, and questions the long-term sustainability and generalizability of such rapid results. He emphasizes the need for studies with hundreds to thousands of people, especially within the context of ketogenic diets, before recommending these supplements.
Dr. Westman agrees with Dr. Ham's focus on factors beyond LDL, such as clotting factors (fibrin, platelets, addressed by Vitamin K2), and blood pressure. He points out that plaque in one artery (e.g., neck) doesn't necessarily reflect plaque in others (e.g., coronary arteries). While pomegranate and Nattokinase address oxidation, HDL transport, and fibrin, he expresses concern that Dr. Ham didn't emphasize dietary improvements beyond these supplements.
Dr. Ham concludes that lifestyle modifications, in conjunction with or instead of drugs, can reverse plaque. Dr. Westman reiterates the need for a comprehensive dietary approach in addition to specific supplements. He is closely observing research on keto dieters with high LDL levels who do not experience proportional heart disease progression, suggesting that the traditional LDL-centric paradigm needs refinement. He hopes newer, more effective paradigms for treating heart disease will emerge and eventually replace older ones.